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OBJECTIVES: To assess the cost-effectiveness of anas-
trozole (ArimidexTM) as adjuvant treatment in post-
menopausal hormone receptor positive (HR+), early
(non-metastasised) breast cancer. METHODS: A Markov
state transition model was developed over 20 years, sim-
ulating the natural history of postmenopausal HR+ early
breast cancer. Adverse event data as well as direct rates
of disease progression were obtained from the ATAC
(Arimidex, Tamoxifen Alone or in Combination) trial
comparing adjuvant anastrozole with tamoxifen (n =
5215), with a median follow-up duration of 4 years. 
Progression to subsequent health states following initial
disease progression was modeled on the basis of pub-
lished clinical studies. Utility scores for different disease
stages were obtained from published literature. Costs of
breast cancer recurrence (locoregional and distant) and
adverse events were calculated from resource utilisation
obtained through a two-round Delphi consensus panel
(physicians = 7), multiplied with unit costs from the
French health care payer’s perspective at an annual dis-
count rate of 3%. RESULTS: Comparison with EBCTCG
data shows that the model is valid for predicting clinical
outcomes. At a life time horizon of 20 years, incremental
cost effectiveness ratios (ICER) of €13,525 /life year
gained (LYG) and €12,722/Quality adjusted life year
gained are obtained for anastrazole relative to tamoxifen.
Multiple sensitivity analyses show the results to be robust
to relatively large variations in risk reduction by anas-
trozole or cost estimates of disease progression. Out-
comes appear sensitive to the time horizon with an ICER
of €24,950/LYG at 15 years. This impact of time horizon
on cost-effectiveness is a typical ﬁnding in treatment for
early cancer, related to treatment costs incurring during
the initial 5 years whereas beneﬁts (LYG) become appar-
ent after several years through prevention of death from
disease progression. CONCLUSION: Compared to
tamoxifen, anastrozole appears cost-effective for adju-
vant treatment of postmenopausal HR+ early breast
cancer and lies within acceptable cost-effectiveness 
benchmarks.
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OBJECTIVES: ENF blocks fusion of HIV-1 to host cells.
Phase III trials, TORO 1 & 2, demonstrated that ENF in
combination with optimized backgrounds (OB) provided
additional viral suppression and immune reconstitution
compared to OB alone in antiretroviral experienced
patients. We constructed two interactive models to eval-
uate cost-effectiveness and budgetary impact of ENF.
METHODS: Treatment effects on time to virological
failure, 24-week change from baseline in HIV-1 viral load
and CD4+ cell count were from clinical ﬁndings. Time to
immunological failure (IF), AIDS-deﬁning event (ADE),
and death were estimated by linking data mathematically
to published disease-progression models. Direct costs
were calculated from published estimates. The incremen-
tal cost per quality-adjusted life year (QALY) gained
(ICER) was estimated using the societal perspective. The
BIA estimated ﬁnancial impact of adding ENF to formu-
laries across total health care costs versus pharmacy costs
only. Total costs of treating eligible HIV population for
four years and cost per member per month (PMPM) were
calculated for a hypothetical health plan. Most input 
variables can be changed to reﬂect plan characteristics
and patient experiences. RESULTS: Treatment effects of
ENF + OB vs. OB alone indicate a decline in the annual
rate of IF from 73% on OB to 37% on ENF + OB. The
combined treatment effects are predicted to increase mean
survival by 1.6 years (1.3 QALYs). The ICER of ENF +
OB is estimated to be $36,238/QALY. BIA showed added
costs of $5,074,472 ($1.69 PMPM) for ENF treatment in
the ﬁrst year, and $1,222,279 ($0.28 PMPM) annually in
subsequent years. Sensitivity analyses showed that ADE
risk as a function of CD4, time to IF, and baseline CD4+
cell count most affected cost-effectiveness estimates.
CONCLUSIONS: Combining drug plan beneﬁts with
CEA enables a more comprehensive understanding of the
economic implications of ENF. The transparent and 
interactive models allow Health care decision-makers to
understand and utilize them to estimate ENF’s cost-
effectiveness and budgetary impact easily.
